Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

New Phesi analysis of 167 million patient records finds colorectal cancer has largest volume of real-world data, but oncology trials still lack modernization Phesi CEO urges shift to “precision ...

Trastuzumab deruxtecan belongs to a group of antineoplastic drugs known as antibody-drug conjugates (ADCs). This type of ...

A new study published in the Annals of Surgical Oncology revealed that individuals with little muscle mass, segmentectomy ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Emrelis is the first FDA-approved treatment for previously treated patients with locally advanced or metastatic non-squamous non-small cell lung cancer with high c-Met protein overexpression.

Ideaya Biosciences, Inc. progresses trials for uveal melanoma and solid tumors, with key upcoming data milestones. Click for ...

Former President Joe Biden was hospitalized overnight last Friday in Philadelphia for “further evaluation” of a small nodule ...